Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Exclusion Criteria

• •Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
• •Type 1 diabetes mellitus
• •Symptomatic hypotension or systolic BP \<95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2
• •Current acute decompensated HF or hospitalization due to decompensated HF \<4 weeks prior to enrolment
• •MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment
• •Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization
• •Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device
• •Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
• •HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
• •Symptomatic bradycardia or second or third degree heart block without a pacemaker
• •Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization